Cargando…

Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma

SIMPLE SUMMARY: Despite success of targeted therapy, cancer cells very often find a way to survive treatment; this eventually causes a tumor to relapse. In a particular type of lymphoma carrying a specific chromosomal rearrangement named anaplastic large-cell lymphoma (ALCL), selective drugs targeti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arosio, Giulia, Sharma, Geeta G., Villa, Matteo, Mauri, Mario, Crespiatico, Ilaria, Fontana, Diletta, Manfroni, Chiara, Mastini, Cristina, Zappa, Marina, Magistroni, Vera, Ceccon, Monica, Redaelli, Sara, Massimino, Luca, Garbin, Anna, Lovisa, Federica, Mussolin, Lara, Piazza, Rocco, Gambacorti-Passerini, Carlo, Mologni, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431561/ https://www.ncbi.nlm.nih.gov/pubmed/34503232 http://dx.doi.org/10.3390/cancers13174422

Ejemplares similares

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling
por: Ceccon, Monica, et al.
Publicado: (2018)

NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
por: Mologni, Luca, et al.
Publicado: (2015)

Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
por: Redaelli, Sara, et al.
Publicado: (2016)

New Advances in Liquid Biopsy Technologies for Anaplastic Lymphoma Kinase (ALK)—Positive Cancer
por: Villa, Matteo, et al.
Publicado: (2021)

An Imatinib–non‐responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization
por: Crespiatico, Ilaria, et al.
Publicado: (2019)

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes
por: Sharma, Geeta Geeta, et al.
Publicado: (2018)

Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer
por: Awad, Mark M., et al.
Publicado: (2017)

Synergistic Effects of Combined Wnt/KRAS Inhibition in Colorectal Cancer Cells
por: Mologni, Luca, et al.
Publicado: (2012)

The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhibition
por: Mologni, Luca, et al.
Publicado: (2017)

P1235: INVESTIGATION OF THE CO-MUTATIONAL LANDSCAPE OF ALK-POSITIVE ALCL
por: Villa, Matteo, et al.
Publicado: (2023)

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells()
por: Mologni, Luca, et al.
Publicado: (2018)

Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase
por: Mologni, Luca, et al.
Publicado: (2022)

Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia
por: Fontana, Diletta, et al.
Publicado: (2020)

Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
por: Fontana, Diletta, et al.
Publicado: (2021)

ERG Deregulation Induces PIM1 Over-Expression and Aneuploidy in Prostate Epithelial Cells
por: Magistroni, Vera, et al.
Publicado: (2011)

Correction to “Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase”
por: Mologni, Luca, et al.
Publicado: (2022)

DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients
por: Malighetti, Federica, et al.
Publicado: (2023)

A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK(+) lymphomas
por: Rindone, Giovanni, et al.
Publicado: (2022)

In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib
por: Redaelli, Sara, et al.
Publicado: (2015)

ALK Kinase Domain Mutations in Primary Anaplastic Large Cell Lymphoma: Consequences on NPM-ALK Activity and Sensitivity to Tyrosine Kinase Inhibitors
por: Lovisa, Federica, et al.
Publicado: (2015)

FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery
por: Piazza, Rocco, et al.
Publicado: (2012)

De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways
por: Magistroni, Vera, et al.
Publicado: (2019)

Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients
por: Fontana, Diletta, et al.
Publicado: (2023)

Increased Tenascin C, Osteopontin and HSP90 Levels in Plasmatic Small Extracellular Vesicles of Pediatric ALK-Positive Anaplastic Large Cell Lymphoma: New Prognostic Biomarkers?
por: Lovisa, Federica, et al.
Publicado: (2021)

Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases
por: Spinelli, Roberta, et al.
Publicado: (2013)

Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases
por: Spinelli, Roberta, et al.
Publicado: (2014)

STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma
por: Lobello, Cosimo, et al.
Publicado: (2020)

CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data
por: Piazza, Rocco, et al.
Publicado: (2013)

RNY4 in Circulating Exosomes of Patients With Pediatric Anaplastic Large Cell Lymphoma: An Active Player?
por: Lovisa, Federica, et al.
Publicado: (2020)

ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine
por: Fontana, Diletta, et al.
Publicado: (2020)

OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes
por: Rocco, Piazza, et al.
Publicado: (2017)

Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes
por: Piazza, Rocco, et al.
Publicado: (2017)

Quantification of Minimal Disease by Digital PCR in ALK-Positive Anaplastic Large Cell Lymphoma: A Step towards Risk Stratification in International Trials?
por: Damm-Welk, Christine, et al.
Publicado: (2022)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Effects of blocking CD24 and CD47 ‘don't eat me’ signals in combination with rituximab in mantle‐cell lymphoma and chronic lymphocytic leukaemia
por: Aroldi, Andrea, et al.
Publicado: (2023)

We shall overcome (drug resistance) some day
por: Sharma, Geeta G., et al.
Publicado: (2019)

Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia
por: Gambacorti‐Passerini, Carlo, et al.
Publicado: (2022)

miR-939 acts as tumor suppressor by modulating JUNB transcriptional activity in pediatric anaplastic large cell lymphoma
por: Garbin, Anna, et al.
Publicado: (2020)

SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub
por: Piazza, Rocco, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_c1ktd6h4f415bbrdajtepeq6f8